MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie.

MicroRNA (miR)-31 serves a key role in various biological processes, including tumor development, angiogenesis and inflammation. Whether miR-31 is involved in the pathological processes of arteriosclerosis obliterans (ASO) remains to be elucidated, as does the mechanism of miR-31 regulation of arterial smooth muscle cells (ASMCs). In the present study, miR-31 expression was detected by reverse transcription-quantitative polymerase chain reaction and hybridization, and was significantly upregulated in human ASO arterial walls compared with normal arterial walls (P<0.001). In addition, miR-31 proliferation was detected by Cell Counting Kit-8 and EdU assays; proliferation was significantly promoted in platelet-derived growth factor (PDGF)-BB-induced human ASMCs (HASMCs) (P<0.001). miR-31 migration was detected by transwell and wound closure assays, and was revealed to be promoted in PDGF-BB-induced HASMCs (P<0.001). Lastly, HASMCs were transfected with miR-31 mimics and inhibitors, and negative controls. A dual-luciferase reporter assay was performed to verify that mitofusin-2 (MFN2) was a direct target of miR-31 and that MFN2 expression was significantly downregulated by miR-31 at a post-transcriptional level in HASMCs as detected by western blotting (P<0.01). These findings suggest that miR-31 is able to promote the proliferation and migration of HASMCs, at least in part, by targeting MFN2. The results of the present study provide novel insight into the underlying mechanisms and roles of miR-31/MFN2 in the pathology of ASO, which may offer a potential therapeutic target for the treatment of ASO.